share_log

424B3: Prospectus

424B3: Prospectus

424B3:募资说明书
美股SEC公告 ·  2024/11/09 06:26

Moomoo AI 已提取核心信息

Aclarion, Inc., a healthcare technology company, has filed a prospectus with the SEC detailing the offer and resale of up to 27,515,153 shares of common stock. This includes up to 21,830,104 shares issuable upon conversion of Series C Convertible Preferred Stock and up to 5,685,049 shares issuable upon exercise of warrants, both resulting from a private investment in public equity (PIPE) financing under a Securities Purchase Agreement dated September 30, 2024. Aclarion is not selling any securities under this prospectus and will not receive proceeds from the sale of shares by the Selling Stockholders. However, the company may receive approximately $1.2 million from the cash exercise of the Common Warrants. The shares are to be sold by Selling Stockholders from time to time, at market prices...Show More
Aclarion, Inc., a healthcare technology company, has filed a prospectus with the SEC detailing the offer and resale of up to 27,515,153 shares of common stock. This includes up to 21,830,104 shares issuable upon conversion of Series C Convertible Preferred Stock and up to 5,685,049 shares issuable upon exercise of warrants, both resulting from a private investment in public equity (PIPE) financing under a Securities Purchase Agreement dated September 30, 2024. Aclarion is not selling any securities under this prospectus and will not receive proceeds from the sale of shares by the Selling Stockholders. However, the company may receive approximately $1.2 million from the cash exercise of the Common Warrants. The shares are to be sold by Selling Stockholders from time to time, at market prices or in negotiated transactions. Aclarion's common stock is listed on the Nasdaq Capital Market under the symbol 'ACON.' The company has received deficiency letters from Nasdaq for not complying with the minimum bid price and stockholders' equity requirements and is subject to potential delisting. Aclarion plans to implement a reverse stock split to regain compliance. The company has appealed the delisting notices and has been granted an extension until January 31, 2025, to demonstrate compliance.
Aclarion,Inc.,一家医疗科技公司,已向SEC提交招股说明书,详细说明最多27,515,153股普通股的发行和转售。其中包括最多21,830,104股可通过C系列可转换优先股转换而发行,最多5,685,049股可通过行使认股权证而发行,这两者都是由于2024年9月30日根据《证券购买协议》进行的私募股权投资(PIPE)融资而导致。Aclarion不会在本招股说明书下出售任何证券,并不会从销售股票的持股股东处收到款项。然而,公司可能会从普通认股权的现金行使中收到约120万美元。股票将由持股股东按市场价格或协商交易的形式不时出售。Aclarion的普通股在纳斯达克资本市场上以标的'ACON'上市。该公司已收到纳斯达克发出的违规最低买盘价和股东权益要求不符的不足通知,可能会被摘牌。Aclarion计划实施股份的反向拆分以恢复合规性。公司已上诉摘牌通知,并已获得延期时间直至2025年1月31日展示合规性。
Aclarion,Inc.,一家医疗科技公司,已向SEC提交招股说明书,详细说明最多27,515,153股普通股的发行和转售。其中包括最多21,830,104股可通过C系列可转换优先股转换而发行,最多5,685,049股可通过行使认股权证而发行,这两者都是由于2024年9月30日根据《证券购买协议》进行的私募股权投资(PIPE)融资而导致。Aclarion不会在本招股说明书下出售任何证券,并不会从销售股票的持股股东处收到款项。然而,公司可能会从普通认股权的现金行使中收到约120万美元。股票将由持股股东按市场价格或协商交易的形式不时出售。Aclarion的普通股在纳斯达克资本市场上以标的'ACON'上市。该公司已收到纳斯达克发出的违规最低买盘价和股东权益要求不符的不足通知,可能会被摘牌。Aclarion计划实施股份的反向拆分以恢复合规性。公司已上诉摘牌通知,并已获得延期时间直至2025年1月31日展示合规性。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息